Podocalyxin is a marker of poor prognosis in colorectal cancer by Kaprio, Tuomas et al.
Kaprio et al. BMC Cancer 2014, 14:493
http://www.biomedcentral.com/1471-2407/14/493RESEARCH ARTICLE Open AccessPodocalyxin is a marker of poor prognosis in
colorectal cancer
Tuomas Kaprio1,2*, Christian Fermér3, Jaana Hagström2,5, Harri Mustonen1, Camilla Böckelman1,2, Olle Nilsson4
and Caj Haglund1,2Abstract
Background: Over two decades ago, a proposal was that two different colorectal cancer (CRC) entities existed,
based on tumour location either proximal (right) or distal (left) of the splenic flexure. Proximal and distal tumours
exhibit different clinical, epidemiological, and biological characteristics. Improvement of the prognostic evaluation
of CRC requires new molecular markers. Podocalyxin-like 1 (PODXL), an anti-adhesive transmembrane sialomucin, is
associated with an aggressive tumour phenotype and poor prognosis. For colorectal cancer, it has been suggested
to be a marker of poor prognosis. The aim of this study was to investigate the role of PODXL in CRC by use of a
novel monoclonal antibody.
Methods: In 1983–2001, 840 consecutive colorectal cancer patients were treated at Helsinki University Central
Hospital, of whom 767 were successfully scored for PODXL immunohistochemical expression from tumour tissue
microarrays by use of a novel monoclonal in-house antibody. Associations of PODXL expression and tumour
location with other clinicopathological variables were explored by Fisher’s exact-test, linear-by- linear association
test, and binary logistic regression. Survival analyses were done by the Kaplan-Meier method and Cox proportional
hazards model.
Results: PODXL protein expression was high in 44 (5.7%) specimens. High expression associated strongly with poor
differentiation (p < 0.0001), advanced stage (p = 0.011), and location of the tumour in the right hemicolon (RHC)
(p < 0.001). Tumours of the RHC were more poorly differentiated (p < 0.0001) and showed higher PODXL expression
(p < 0.001).
High PODXL expression associated significantly with higher risk for disease-specific death from CRC (hazard ratio
(HR) = 2.00; 95% confidence interval (CI) 1.31–3.06, p = 0.001) and also in the subgroups of left hemicolon (LHC)
cancers (HR = 2.60; 95% CI 1.45–4.66, p = 0.001) and rectal cancers (HR = 3.03; 95% CI 1.54–5.60, p = 0.001). Results
remained significant in multivariable analysis (respectively, HR = 1.82; 95% CI 1.15–2.86, p = 0.01; HR = 2.59; 95% CI
1.41–4.88, p = 0.002; and HR = 2.69; 95% CI 1.30–5.54, p = 0.007).
Conclusion: Podocalyxin was an independent factor for poor prognosis in colorectal cancer and in the subgroups
of left hemicolon and rectum. This is, to our knowledge, the first evidence of such difference in PODXL expression,
its function possibly being dependent upon tumour location.
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Colorectal cancer (CRC) is the world’s third most com-
mon cancer with over one million new cases and half a
million deaths annually. Early detection, radical surgical
and adjuvant chemotherapy are important for clinical
outcome. The most crucial factor today for predicting
patient outcome is stage of disease at diagnosis; roughly
40% has localised disease and another 40% regional dis-
ease [1].
Over two decades ago, Bufill [2] proposed that two dif-
ferent CRC entities exist according to location of the
tumour either proximal to the splenic flexure (RHC= right
hemicolon; caecum, ascending colon, hepatic flexure, and
transverse colon) or distal to it (LHC = left hemicolon;
splenic flexure, descending colon, sigmoid colon, and rec-
tum). Cancers of the RHC (RHCC) and LHC (LHCC) ex-
hibit different clinical and biological characteristics [3-5].
Adjuvant therapy is today standard care for stage-III
patients, giving an absolute 10% increase in 5-year over-
all survival, but for stage-II patients, the benefit of
adjuvant therapy is still unclear. In stage-II patients, T4-
stage, high histological grade, vascular invasion, tumour
obstruction, bowel perforation, and inadequate lymph
node resection favour the need for adjuvant therapy,
even though limited prospective data support this [6].
Podocalyxin-like 1 (PODXL) is an anti-adhesive trans-
membrane sialomucin expressed by normal vascular
endothelia [7], breast epithelial cells [8], haematopoietic
progenitors [9], and renal podocytes [10]. It is also a well-
known stem cell marker [11], and is closely related to stem
cell marker CD34 and to endoglycan. It is thought to
regulate cell morphology and adhesion through its con-
nections to intracellular proteins and to extracellular
ligands [12-15]. Aberrant expression or allelic variation of
PODXL or both occurs in many cancer forms, including
renal cell carcinoma, breast, colorectal, testicular, prostate,
and pancreatic cancer [8,13,16-20]. In renal cell car-
cinoma, breast, and colorectal cancer it has also been an
independent predictor of poor prognosis. The role of
PODXL is not yet fully understood; though it evidence
shows it to participate in epithelial-mesenchymal transi-
tion [21] and it interacts with different mediators of me-
tastasis [13-15,20,22].
The aim of this study was to validate in a cohort of 840
CRC patients the role of PODXL expression as a marker
of poor prognosis and to evaluate its association with cli-
nicopathological variables by use of a novel monoclonal
antibody. This new antibody HES9, produced against em-
bryonic stem cells, is demonstrated to recognise PODXL.
Methods
Patients
The study population comprised 840 consecutive colorec-
tal cancer patients surgically treated in 1983–2001 at theDepartment of Surgery, Helsinki University Central
Hospital. Their median age was 66. The Finnish Popula-
tion Register Centre provided the follow-up vital status
data needed to compute survival statistics, and Statistics
Finland provided cause of death for all those deceased.
Median length of follow-up was 5.1 year (range 0–25.8),
with a 5-year disease-specific overall survival rate of 58.9%
(95% Cl 55.0–62.8%). The Surgical Ethics Committee of
Helsinki University Central Hospital (Dnro HUS 226/E6/
06, extension TMK02 §66 17.4.2013) and the National
Supervisory Authority of Welfare and Health (Valvira
Dnro 10041/06.01.03.01/2012) approved the study.
Preparation of tumour tissue microarrays
Formalin-fixed and paraffin-embedded tumour samples
came from the archives of the Department of Pathology,
University of Helsinki. An experienced pathologist marked
representative areas of tumour samples on haematoxylin-
and eosin- stained tumour slides. Three 1.0-mm-diameter
punches taken from each sample were mounted on reci-
pient paraffin block with a semiautomatic tissue microarray
instrument (Beecher Instruments, Silver Spring, MD, USA)
as described [23].
PODXL monoclonal antibody
For the novel monoclonal antibody (mAb) HES9 used here,
immunization of mice was with the undifferentiated
human embryonic (hES) stem cell line SA167 (Cellartis,
Gothenburg, Sweden, www.cellectis-bioresearch.com); and
by conventional hybridoma technology [24] we established
hybridoma cell lines producing mAbs against hES cells.
Mimotope analysis, immunoprecipitation, and mass-
spectrometry identified the target antigen as PODXL. The
mimotope sequence corresponds to amino acid residues
189 to 192 in the PODXL protein sequence (NCBI Refer-
ence Sequence: NP_001018121.1). For a detailed descrip-
tion see Additional file 1.
Immunohistochemistry
Tumour tissue microarray blocks were freshly cut into
4-μm sections. After deparaffinization in xylene and re-
hydration through a gradually decreasing concentration
of ethanol to distilled water, slides were treated in a
PreTreatment module (Lab Vision Corp., Fremont, CA,
USA) in Tris–HCl (pH 8.5) buffer for 20 min at 98°C for
antigen retrieval. Staining of sections was performed in
an Autostainer 480 (Lab Vision) by the Dako REAL
EnVision Detection system, Peroxidase/DAB+, Rabbit/
Mouse (Dako, Glostrup, Denmark). Tissues were incu-
bated with the mouse mAb HES9, at dilution of 1:500
(=5 μg/ml) for one hour at room temperature. A sample
of renal tissue served as a positive control in each stain-
ing series.
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HES9 expression in tumour cells was mainly cytoplas-
mic, evenly distributed, and often granular. Membranous
positivity was seen only in cells with strong cytoplasmic
staining. Positivity in tumour cells was uniform, with no
nuclear expression. Cytoplasmic HES9 immunoreactivity
was scored independently by T.K. and J.H., who were
blinded to clinical data and outcome. Negative cyto-
plasmic staining was scored as 0, weakly positive as 1,
moderately positive as 2, and strongly positive as 3. The
highest score of the triplicates of each sample was con-
sidered representative for analysis. Differences in scoring
were discussed until consensus.
Statistical analyses
For statistical purposes, categories of PODXL expression
were dichotomised into low (0–2) and high (3). Evaluation
of the association between PODXL expression and clini-
copathological parameters was done with the Fisher
exact-test or linear-by-linear association test for ordered
parameters. The effect of laterality on PODXL expression
was confirmed by binary logistic regression adjusted for
differentiation, age, gender, and Dukes classification.
Disease-specific overall survival was counted from date of
surgery to date of death from colorectal cancer, or until
end of follow-up. Survival analysis was done by the
Kaplan-Meier method and compared by the log rank test.
The Cox regression proportional hazard model served for
uni- and multivariable survival analysis, adjusted for sex,
age, Dukes classification, and differentiation. Testing of
the Cox model assumption of constant hazard ratios over
time involved including a time-dependent covariate sepa-
rately for each testable variable. Hazard ratios of differen-
tiation and Dukes class D were analyzed in two periods (0
to 1.25 and 1.25 to 5 years) in order to meet the assump-
tions of the Cox model, and the time-dependent COX
model was used. Interaction terms were considered, but
no significant interactions found. All test were two-sided.
A p-value of 0.05 was considered significant. All statisticalFigure 1 Immunohistochemical staining patterns of mAb HES9. Repre
negative, (B) weakly positive, (C) moderately positive, and (D) strongly pos
magnification was × 40.analyses were done with SPSS version 20.0 (IBM SPSS
Statistics, version 20.0 for Mac; SPSS, Inc., Chicago, IL,
USA, an IBM Company).
Results
Immunohistochemistry
Of 840 tumours represented in the TMA, PODXL cyto-
plasmic staining could be evaluated in 767 (91.3%): 41
(5.3%) negative for PODXL, 430 (56.1%) showing weak
staining, 252 (32.9%) moderate staining, and 44 (5.7%)
strong staining. Representative immunostainings are in
Figure 1A-D. In the vast majority of tumours, PODXL
stained evenly throughout the cytoplasm in a granular
manner, and positivity was visible in all tumour cells.
Neither nuclear nor cell membranous immunopositivity
occurred.
Association of PODXL expression with clinicopathological
parameters
Analysis of the association between PODXL and clinico-
pathological parameters revealed a strong association bet-
ween high PODXL expression and poor differentiation
(p < 0.0001), advanced stage (p = 0.012), and location in
the RHC (p < 0.001). PODXL expression did not associate
with age, gender, nor tumour location (colon vs. rectum)
(Table 1).
Association of tumour location with clinicopathological
parameters
Analysis of the differences between cancers of the RHC
and LHC showed cancers of the RHC to exhibit higher
expression of PODXL (p < 0.001) and be more poorly dif-
ferentiated (p < 0.0001) (Table 2). The effect of laterality
on high PODXL expression was confirmed by binary lo-
gistic regression adjusted for differentiation, age, gender,
and Dukes classification (OR = 2.27; 95% CI 1.17–4.39,
p = 0.015). Laterality did not associate with age or gender
(Additional file 2).sentative images of PODXL expression in colorectal cancer. (A) PODXL-
itive immunoreactivity. MAb HES9 recognises PODXL protein. Original
Table 1 Association between HES9 expression and
clinicopathological parameters
HES9 expression
Low High
n (%) 723 (94.3) 44 (5.7) p-value
Age, years
<65 309 (42.7) 16 (36.4) 0.436
≥65 414 (57.3) 28 (63.6)
Gender
Male 402 (44.4) 24 (54.5) 1.000
Female 321 (55.6) 20 (45.5)
Dukes
A 109 (15.1) 2 (4.5) 0.012
B 259 (35.8) 13 (29.5)
C 196 (27.1) 14 (31.8)
D 159 (22.0) 15 (34.1)
Grade (WHO)
1 26 (3.6) 0 (0) <0.0001
2 514 (71.5) 11 (25.0)
3 161 (22.4) 25 (56.8)
4 18 (2.5) 8 (18.2)
Missing 4
Location
Colon 372 (51.5) 28 (63.6) 0.123
Rectum 351 (48.5) 16 (36.3)
Side
Right 189 (26.1) 23 (52.3) <0.001
Left 534 (73.9) 21 (47.7)
Fisher exact-test for 2 × 2 tables and linear-by-linear association test for tables
with more than two rows. Missing data excluded from analyses. MAb HES9
recognises PODXL protein.
Table 2 Association of tumour side and
clinicopathological parameters
Location of the tumour
Right hemicolon Left hemicolon
n (%) 227 (27.0) 613 (73.0) p-value
Age, years
<65 89 (39.2) 271 (44.2) 0.209
≥65 138 (60.8) 342 (55.8)
Gender
Male 119 (52.4) 347 (56.6) 0.310
Female 108 (47.6) 266 (43.4)
Dukes
A 21 (9.3) 104 (17.0) 0.129
B 85 (37.4) 209 (34.1)
C 70 (30.8) 161 (26.3)
D 51 (22.5) 139 (22.7)
Grade (WHO)
1 7 (3.1) 22 (3.6) <0.0001
2 127 (56.7) 444 (72.7)
3 74 (33.0) 128 (20.9)
4 16 (7.1) 17 (2.8)
Missing 3 2
HES9
Low 189 (89.2) 534 (96.2) <0.001
High 23 (10.8) 21 (3.8)
Missing 15 58
Fisher exact-test for 2 × 2 tables and linear-by-linear association test for tables
with more than two rows. Missing data excluded from analyses. MAb HES9
recognises PODXL protein.
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Kaplan-Meier analysis showed a significantly poorer dis-
ease-specific survival (DSS) for colorectal cancer patients
with high PODXL expression (p = 0.011) (Figure 2A).
Five-year DSS for patients was 42.5% for high PODXL ex-
pression (95% CI 27.2–57.8%) and for low expression
59.8% (95% CI 56.1–63.5%).
Because of the difference in biological and anatomical
background of the right and left colorectum, we also stra-
tified our results for colon vs. rectum, and for RHC vs.
LHC. For colon and RHC cancer patients we found no
evidence of any difference in survival between patients
with high compared to low PODXL expression (Additional
file 3). Rectal cancer patients with high PODXL expression
had significantly poorer DSS than did those with low
expression (p = 0.009). Five-year DSS for rectal cancer
patients was 30.8% (95% CI 5.7–55.9%) for high and
60.7% (95% CI 55.2–66.2) and for low PODXL tumourexpression. A similar effect of high PODXL expression
occurred in LHCC (p = 0.005). Five-year DSS for LHCC
patients was 33.3% (95% CI 11.5–55.1%) for high vs. 60.2%
(95% CI 55.9–64.5%) for low PODXL tumour expression
(Figures 2B-C). No significant difference in DSS emerged
between tumours having negative, weak or moderate
PODXL expression in CRC, or in any of the subgroups
(data not shown).
Cox regression univariable analyses confirmed these re-
sults. In multivariable survival analyses adjusted for age,
gender, Dukes classification, and differentiation grade,
high PODXL expression remained significant for the
whole CRC material as well as for the subgroups of rectal
cancer and cancer of the LHC (Table 3).
Discussion
Here we used a novel mAb HES9 produced by hybridoma
technology against human embryonic stem cells to show
that this new mAb is specific for PODXL, known to be a
stem cell marker [11]. By immuhistochemical staining, we
show that in CRC, PODXL is an independent prognostic
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Figure 2 High expression of PODXL is associated with poor prognosis. Disease-specific survival analysis according to the Kaplan-Meier
method for HES9 expression in (A) colorectal cancer, (B) rectal cancer, and (C) cancer of the left hemicolon. Log-rank test was the test used. MAb
HES9 recognises PODXL protein.
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analyzed separately tumours from the colon and rectum
as well as right and left hemicolon. To our knowledge
these are the first results to show that PODXL is an inde-
pendent prognostic factor in subgroups of LHCC and
rectal cancers. We also show a difference in PODXL ex-
pression depending on tumour location.
We also show that immunostaining of PODXL by
our new mAb gives prognostic results similar to thoseTable 3 Cox uni-and multivariable analysis of relative risk of
hemicolon cancer within 5 years by HES9 expression
Colorectal cancer-specific survival Left hemicolon
HR (95% CI) p-value n (events) HR (95% CI)
Univariable
HES9 low 1.00 723 (266) 1.00
High 2.00 (1.31–3.06) 0.001 44 (23) 2.60 (1.45–4.66)
Multivariable
HES9 low 1.00 719 (266) 1.00
High 1.82 (1.15–2.86) 0.01 44 (23) 2.59 (1.41–4.88)
Abbreviations: CI confidence interval, HR Hazard ratio. Multivariable analysis included
(G1/2 vs G3/4). MAb HES9 recognises PODXL protein.achieved by the commercial polyclonal antibody (HPA
2110, Atlas Antibodies, Stockholm, Sweden) [17,18]. The
antigenic determinant of the polyclonal PODXL antibody
is amino acid residues 278–415, whereas our antibody re-
acts with amino acid residues 189–192. One proposal is
that distinct membranous PODXL expression, but not
cytoplasmic expression, associates with poor prognosis in
different cancers [17,25]. Interestingly, staining by our
monoclonal antibody was mainly cytoplasmic in cancerdeath from colorectal cancer, rectal cancer, and left
cancer-specific survival Rectal cancer-specific survival
p-value n (events) HR (95% CI) p-value n (events)
534 (194) 1.00 351 (125)
0.001 21 (12) 3.03 (1.54–5.60) 0.001 16 (9)
532 (194) 1.00 351 (125)
0.002 21 (12) 2.69 (1.30–5.54) 0.007 16 (9)
adjustment for gender, age (>/≤65 years), Dukes class, differentiation grade
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The reason for the difference in cancer cells compared to
benign cells is not known. The difference in staining pat-
tern may reflect different PODXL function in cancer
compared to normal tissue. It is also possible that the
HES9 mAb in cancer cells recognices splice variants not
expressed in cytoplasm of normal cells. Similar change in
expression from membranous to cytoplasmic is also seen
for instance in some Toll-like receptor (TLR) stainings
[26]. The proportion of tumours with high PODXL ex-
pression was relatively small compared to the proportion
in previous studies (5.7% vs. 7.9–13.4%) ([17,18], which
could be explained by differences in antibody, patient
series, staining methods, and staining evaluation/cut- off
points. Similar results to ours has been reported in uterine
endometroid carcinoma, where the ectopic apical ex-
pression of PODXL in benign uterine endometroid tissue
was transformed into cytoplasmic expression in car-
cinoma [27]. Further studies compare the expression pat-
tern of these two antibodies in the same patient series.
High expression of PODXL was an independent mar-
ker of poor prognosis in colorectal cancer, but no dif-
ference emerged between moderate, low, or negative
expression. These results are similar to earlier ones on
colorectal [17,18] and breast cancer [8].
Over two decades ago Bufill’s [2] suggestion of sub-
division of CRC by tumour location was not based solely
on anatomical site. It is based also on developmental dif-
ferences, because the RHC is derived from midgut and
perfused by the superior mesenteric artery with a multi-
layered capillary network, whereas the LHC is derived
from hindgut and perfused by the inferior mesenteric
artery with a single layer capillary network.
Here, cancers of the RHC were more poorly differen-
tiated, had higher PODXL expression, and were in older
patients, more often female, although differences in age
and gender were not statistically significant. Results are
in concordance with earlier ones, because cancers of the
right hemicolon tend to be less differentiated and more
locally advanced, the patients tend to be older, and more
often female [4,5,28]. On the other hand, a recent study
by Yamauchi [29] suggests no discrete transition point at
the splenic flexure, but a gradual change in histological
and molecular characteristics from ascending colon to
rectum.
The higher expression of PODXL in the RHCC was
expected, because these cancers are more poorly dif-
ferentiated and PODXL expression correlates with dif-
ferentiation. On the other hand, we show that the
difference in PODXL expression between right and left
sides is independent of other predictors of survival.
Interestingly, only in the LHCC group was high PODXL
expression a sign of poor prognosis, not in the RHCC
group. This is unlikely due to inadequate statisticalpower in our study, as there were 237 cases of RHCC,
suggesting a different role for PODXL in tumours of the
RHC compared to the LHC.
By the TMA technique, only a small proportion of the
tumours are evaluated compared to studies of whole tissue
sections. Moreover, for technical reasons, up to 9% of the
specimens were lost in the TMA-production and -staining
process. On the other hand, TMA allows analysis of larger
patient cohorts. The strength of this study is a large, well-
characterised CRC-patient cohort with long follow-up
time that permitted subgroup analyses of patients with
various tumour locations.
Conclusion
These results validate the role of PODXL expression as a
prognostic marker in CRC. We also showed the expres-
sion and possibly even function not to be universal
throughout tumours of the colon and rectum. These
findings confirm that CRC should not be considered a
uniform disease and indicate the possibilities for more in-
dividual diagnosis and treatment. Further studies should
aid in understanding the function of PODXL in CRC and
the reasons for differences in expression between cancers
of the RHC and the LHC.
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